Recent Finacing
Recent Raise
Aulos Bioscience develops AI-designed AU-007, an IgG1 monoclonal antibody that redirects IL‑2 toward effector T and NK cells while sparing Tregs, currently in Phase 1/2 trials for solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Aulos Bioscience.
